Biomark Diagnostics Inc Stock Price, News & Analysis

Welcome to our dedicated page for Biomark Diagnostics news (Ticker: BMKDF), a resource for investors and traders seeking the latest updates and insights on Biomark Diagnostics stock.

BioMark Diagnostics Inc. (BMKDF) regularly issues news and updates about its work in liquid biopsy-based early cancer detection, with a strong emphasis on lung cancer. The company’s announcements describe progress in applying metabolomics and machine learning to blood-based diagnostics, as well as developments in clinical validation, laboratory capacity, and international collaborations.

Readers of this news feed can follow BioMark’s participation in large-scale clinical studies, such as its role as a core diagnostic partner in the HANSE lung cancer screening trial in Germany and its involvement in multi‑thousand‑patient lung cancer studies in Canada. News items also cover recognition from organizations like ADRIQ and CQDM for multimodal lung cancer screening projects that integrate metabolomic blood tests, clinical data, and artificial intelligence.

Company releases provide detail on peer-reviewed publications, including work accepted in journals such as Frontiers in Oncology that report on machine learning-driven predictive models using pathway-based plasma metabolomic biomarkers. Updates also highlight the expansion of BioMark’s specialty laboratory services in Quebec, equipment upgrades that increase testing capacity, and steps toward laboratory certification and accreditation.

Investors and healthcare professionals can use this page to review announcements on intellectual property milestones, such as patents granted in China and Japan for BioMark’s metabolic liquid biopsy platform, as well as strategic agreements in regions like North Africa. By visiting this news section, users gain a consolidated view of BioMark’s clinical, operational, and strategic developments in oncology diagnostics.